Home
About
Overview
Sharing Data
ORCID
Help
History (7)
Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes.
miR-130b and miR-128a are essential lineage-specific codrivers of t(4;11) MLL-AF4 acute leukemia.
The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment.
Targeting Innate Inflammation Pathways to Treat Ocular Infections
MYC dysregulation in the progression of multiple myeloma.
See All 7 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
MYC dysregulation in the progression of multiple myeloma.
MYC dysregulation in the progression of multiple myeloma. Leukemia. 2020 01; 34(1):322-326.
View in:
PubMed
subject areas
Disease Progression
Humans
Multiple Myeloma
Mutation
Proto-Oncogene Proteins c-myc
authors with profiles
Michael Joseph O'Dwyer